- Home
- MAIA vs GNTA Comparison
MAIA vs GNTA Comparison
Compare MAIA & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAIA | GNTA |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 39.4M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MAIA | GNTA |
|---|---|---|
| Price | $1.20 | $1.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 454.0K | 111.6K |
| Earning Date | 11-07-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $1.35 |
| 52 Week High | $2.74 | $10.00 |
Technical Indicators
Market Signals| Indicator | MAIA | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 40.49 |
| Support Level | $1.07 | $1.80 |
| Resistance Level | $1.25 | $2.20 |
| Average True Range (ATR) | 0.12 | 0.24 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 55.93 | 59.77 |
Price Performance
Historical ComparisonAbout MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.